암 유전자 패널 및 암 게놈 프로파일링 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 조직 검사별, 암 패널 유형별, 암 유형별, 용도별, 기술별, 최종사용자별, 지역별, 경쟁별(2019-2029년)

Global Genomic Cancer Panel & Profiling Market was valued at USD 9.95 billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 9.43% through 2029. The Global Genomic Cancer Panel & Profiling Market is undergoing remarkable growth and transformation, driven by advancements in precision medicine and genomic technologies. This market revolves around the thorough analysis of cancer-related genomic alterations to guide personalized treatment strategies. Genomic cancer panels, which consist of sets of genes associated with various cancer types, empower clinicians to pinpoint specific mutations, copy number variations, and other genetic abnormalities within a patient's tumor. This information is pivotal for tailoring therapies, predicting treatment responses, and comprehending the genetic underpinnings of cancer. Next-Generation Sequencing (NGS) technologies are instrumental, allowing for high-throughput and detailed genomic profiling. The market's expansion is spurred by the escalating global cancer incidence, underscoring the necessity for precise diagnostic tools.

The incorporation of artificial intelligence and machine learning augments the interpretation of intricate genomic data, facilitating more precise and expedited insights. Collaborations between biotechnology firms and research institutions drive innovation and the creation of comprehensive genomic profiling solutions. These partnerships advance the comprehension of cancer biology and aid in identifying novel therapeutic targets. The market witnesses a shift towards liquid biopsy approaches, enabling non-invasive and real-time monitoring of cancer-related genetic alterations. Liquid biopsy techniques, such as the examination of circulating tumor DNA (ctDNA), contribute to early detection, treatment monitoring, and the evaluation of minimal residual disease.

Furthermore, the trend towards multi-omic integration, which merges genomic data with transcriptomics, proteomics, and other -omics information, offers a holistic perspective of cancer biology. This integrated approach enhances the identification of biomarkers and potential therapeutic targets, fostering a more thorough understanding of the complex molecular mechanisms underlying different cancer types. As the global healthcare landscape increasingly prioritizes personalized and targeted therapies, the Genomic Cancer Panel & Profiling Market is poised for further growth, delivering innovative solutions for precise cancer diagnostics and treatment decision-making. The continuous evolution of genomic technologies and their applications underscores the market's dynamic nature in advancing the era of personalized oncology.

Key Market Drivers

Advancements in Genomic Technologies

Advancements in genomic technologies have been instrumental in shaping the landscape of the Global Genomic Cancer Panel & Profiling Market, ushering in a new era of precision medicine. Next-Generation Sequencing (NGS) stands as a cornerstone in these advancements, revolutionizing the speed, efficiency, and depth of genomic analysis. The continuous evolution of NGS platforms has enabled researchers and clinicians to conduct comprehensive genomic profiling with unprecedented accuracy and scale. Improved sequencing speed and reduced costs have made genomic profiling more accessible, allowing for the analysis of a broader range of genes and facilitating a deeper understanding of cancer-related genetic alterations. Beyond NGS, other genomic technologies such as microarray-based platforms and digital PCR contribute valuable insights. Microarrays provide a high-throughput method for simultaneously examining the expression levels of multiple genes, aiding in the identification of biomarkers associated with specific cancers.

Digital PCR offers enhanced sensitivity in detecting rare genetic mutations, contributing to the precision of genomic profiling. The integration of artificial intelligence (AI) and machine learning (ML) has emerged as a transformative force in genomic data interpretation. Advanced algorithms analyze vast datasets, helping identify patterns, predict treatment responses, and discover novel genetic markers. This fusion of genomic technologies and AI not only accelerates the analysis process but also enhances the accuracy of identifying clinically relevant genomic alterations. The advent of single-cell genomics represents another breakthrough, allowing researchers to analyze individual cells within a heterogeneous tumor. This technology unveils the intra-tumor heterogeneity and provides a more nuanced understanding of the genetic diversity present in cancers. These collective advancements empower the Genomic Cancer Panel & Profiling Market to offer more comprehensive and precise insights into the genomic landscape of cancers. As these technologies continue to evolve, the market is poised to witness further refinement in diagnostic accuracy, therapeutic decision-making, and the realization of personalized treatment strategies for cancer patients globally.

Rising Cancer Incidence

The Global Genomic Cancer Panel & Profiling Market is significantly influenced by the alarming and escalating incidence of cancer worldwide. The pervasive rise in cancer cases serves as a driving force behind the increasing adoption of genomic technologies for comprehensive cancer profiling. Cancer remains a leading cause of morbidity and mortality globally, with new cases diagnosed each year reaching staggering numbers. This surge in cancer incidence intensifies the need for precise diagnostic tools that can unravel the intricate genetic underpinnings of various cancer types. Genomic cancer panels play a pivotal role in this scenario by offering a systematic approach to analyze the genetic alterations associated with specific cancers. As the diversity of cancer types expands, so does the demand for tailored genomic profiling solutions. The ability of genomic technologies, such as Next-Generation Sequencing (NGS), to analyze a multitude of genes simultaneously provides clinicians with a comprehensive view of the genomic landscape, aiding in the identification of key mutations, copy number variations, and other genetic abnormalities driving cancer progression.

The rising cancer incidence not only emphasizes the urgency for accurate and early diagnosis but also underscores the importance of personalized treatment strategies. Genomic profiling enables clinicians to identify specific genetic markers that guide the selection of targeted therapies, contributing to more effective and tailored interventions. The exploration of new and emerging biomarkers associated with different cancer types is fueled by the need to understand the molecular intricacies of each case, further amplifying the relevance and demand for genomic cancer panels. In conclusion, the relentless increase in cancer incidence acts as a catalyst for the Global Genomic Cancer Panel & Profiling Market, driving advancements in genomic technologies and fostering a paradigm shift towards precision medicine in the fight against cancer.

Precision Medicine Initiatives

Precision medicine initiatives are playing a pivotal role in shaping the trajectory of the Global Genomic Cancer Panel & Profiling Market, ushering in an era of personalized and targeted therapeutic approaches. These initiatives are driven by the recognition that each patient's cancer is unique, necessitating tailored treatment strategies based on the individual's genetic makeup. Genomic cancer panels stand at the forefront of this paradigm shift, enabling comprehensive analysis of the molecular alterations within a patient's tumor. The core principle of precision medicine is to match specific genomic aberrations with targeted therapies, optimizing treatment outcomes and minimizing adverse effects. As genomic technologies, particularly Next-Generation Sequencing (NGS), become more sophisticated and accessible, precision medicine initiatives gain momentum. Clinicians leverage genomic cancer panels to identify key genetic mutations, copy number variations, and other alterations that drive cancer progression.

This information becomes crucial for making informed decisions about the most effective therapies for a particular patient. These initiatives are often part of large-scale collaborative efforts involving healthcare institutions, research organizations, and biotechnology companies. The goal is to create extensive databases of genomic and clinical data, facilitating a deeper understanding of the genetic basis of cancer and refining treatment strategies. The integration of artificial intelligence and machine learning further enhances the interpretation of vast datasets, assisting clinicians in identifying relevant biomarkers and predicting treatment responses. Precision medicine initiatives contribute to the shift from a one-size-fits-all approach to cancer treatment to a more nuanced and individualized methodology. By aligning treatment plans with the specific genomic profile of each patient's cancer, these initiatives not only improve therapeutic efficacy but also pave the way for future advancements in oncology. The Global Genomic Cancer Panel & Profiling Market is intricately linked to the success and expansion of precision medicine initiatives, as they collectively drive innovation and bring about transformative changes in cancer care.

Key Market Challenges

Data Privacy and Security Concerns

Data privacy and security concerns constitute significant challenges within the Global Genomic Cancer Panel & Profiling Market. The extensive generation, storage, and sharing of genomic data raise crucial issues regarding patient confidentiality and protection. Genomic information is inherently sensitive, encompassing an individual's unique genetic makeup and potential predispositions to various health conditions, including cancer. Securing genomic data from unauthorized access, breaches, or misuse is paramount. The fear of data breaches and the potential misuse of this highly personal information contribute to concerns among patients, healthcare providers, and regulatory bodies.

The need to comply with stringent data protection regulations, such as the Health Insurance Portability and Accountability Act (HIPAA) in the United States or the General Data Protection Regulation (GDPR) in Europe, adds an additional layer of complexity. The challenge lies in establishing robust and standardized security measures to safeguard genomic data throughout its lifecycle-from collection and storage to transmission and analysis. Implementing encryption, access controls, and secure data sharing protocols becomes essential. Striking a balance between facilitating data-driven healthcare advancements and ensuring stringent data privacy safeguards is imperative to foster trust among stakeholders and encourage the widespread adoption of genomic cancer panels. Addressing these concerns is critical to realizing the full potential of genomic data in advancing precision medicine and personalized cancer care.

Limited Access to Comprehensive Databases

Limited access to comprehensive databases poses a significant challenge to the Global Genomic Cancer Panel & Profiling Market. The success of precision medicine relies heavily on vast and diverse datasets that encompass genomic and clinical information from a wide range of populations and cancer types. However, the availability of such comprehensive databases is often constrained. Access to extensive datasets is crucial for identifying patterns, understanding the genetic basis of cancers, and discovering relevant biomarkers that can inform personalized treatment strategies. The challenge arises due to factors like restricted sharing of genomic data, varying data protection regulations, and the lack of standardized data-sharing frameworks. Building inclusive and representative databases becomes particularly challenging for rare cancers and underrepresented populations.

These limitations hinder the ability to draw meaningful conclusions from genomic profiling, potentially leaving gaps in our understanding of the genetic intricacies of certain cancers. Efforts to address this challenge involve fostering collaboration among researchers, healthcare institutions, and biotechnology companies to promote the sharing of data while adhering to ethical and legal considerations. Encouraging open data-sharing practices and establishing frameworks that ensure privacy and security can contribute to overcoming the hurdle of limited access to comprehensive databases, unlocking the full potential of genomic cancer panels in advancing precision oncology.

Key Market Trends

Rising Emphasis on Early Detection

The Global Genomic Cancer Panel & Profiling Market is witnessing a rising emphasis on early detection, marking a transformative shift in cancer care. Genomic cancer panels play a pivotal role in this paradigm by enabling the identification of genetic alterations associated with cancer at its incipient stages. Early detection through genomic profiling allows for the identification of specific biomarkers indicative of cancer predisposition or the presence of minimal residual disease. This emphasis on early detection aligns with the broader goal of intervening in cancer progression at its earliest, most treatable phases. Genomic cancer panels contribute to precision oncology by uncovering genetic signatures that may indicate a predisposition to certain cancers, enabling proactive screening and surveillance strategies.

The identification of actionable mutations early on facilitates the selection of targeted therapies, potentially improving treatment efficacy and patient outcomes. As healthcare systems increasingly recognize the value of early detection in reducing the burden of cancer, the adoption of genomic cancer panels for screening and early intervention is expected to rise, shaping a future where personalized, genomic-driven approaches contribute significantly to cancer prevention and early-stage management.

Segmental Insights

Tissue Testing Insights

Based on Tissue Testing, the Liquid tissue testing emerged as the fastest growing segment in the global genomic cancer panel and profiling market, especially for tissue testing. This trend signifies a shift towards utilizing liquid samples for testing, rather than traditional approaches, which is anticipated to gain prominence in cancer diagnosis and treatment. Liquid biopsy techniques, such as the analysis of circulating tumor DNA (ctDNA), offer non-invasive and real-time monitoring of cancer-related genetic changes. This approach is valuable for early detection, treatment monitoring, and assessing minimal residual disease. As liquid tissue testing continues to gain traction, it is expected to play a crucial role in enhancing our understanding of cancer biology and improving patient outcomes through personalized treatment strategies.

Cancer Type Insights

Based on cancer type, the lung cancer segment dominated the Global Genomic Cancer Panel & Profiling Market in 2023. This is ascribed due to its high prevalence and the critical role of genomic profiling in personalized treatment. As the leading cause of cancer-related deaths, lung cancer demands precise molecular analysis for targeted therapies. Genomic panels help identify specific mutations, guiding clinicians in selecting tailored treatments and improving patient outcomes. The increasing awareness of genomic testing benefits in lung cancer management, coupled with advancements in precision medicine, amplifies the prominence of lung cancer within the Genomic Cancer Panel & Profiling market, emphasizing the significance of genomic insights in optimizing therapeutic strategies for this prevalent and challenging malignancy.

Regional Insights

The dominance of the North America segment in the global Genomic Cancer Panel & Profiling Market is underpinned by several key factors. With a robust healthcare infrastructure and advanced research facilities, the region fosters the widespread adoption of genomic cancer profiling technologies. The presence of leading market players and increased investment in research and development initiatives further contribute to the region's leadership position.

A higher prevalence of cancer cases in North America, combined with a proactive approach towards early detection and personalized medicine, drives the demand for genomic cancer panels. The collaborative efforts among research institutions, pharmaceutical companies, and healthcare providers in the region play a pivotal role in enhancing the market's growth trajectory. These collective endeavors solidify North America's dominant position on the global stage of genomic cancer panel and profiling, shaping the landscape of cancer diagnostics and treatment strategies worldwide.

Key Market Players

Agilent Technologies, Inc

ARUP Laboratories Inc

Burning Rock Biotech Limited

U.S. Caris MPI, Inc.

Danaher Corporation

Exact Sciences Corporation

F. Hoffmann-La Roche Ltd

Fulgent Genetics Inc.

Illumina, Inc.

Thermo Fisher Scientific Inc.

Report Scope:

In this report, the Global Genomic Cancer Panel & Profiling Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Genomic Cancer Panel & Profiling Market, By Tissue Testing:

Solid Tissue Testing Liquid Tissue Testing

Genomic Cancer Panel & Profiling Market, By Cancer Panel Type:

Single-Gene Panel Multi-Gene Panel

Genomic Cancer Panel & Profiling Market, By Cancer Type:

Lung Cancer Breast Cancer Colon Cancer Prostate Cancer Others

Genomic Cancer Panel & Profiling Market, By Application:

Clinical Research

Genomic Cancer Panel & Profiling Market, By Technology:

Next-Generation Sequencing (NGS) Polymerase Chain Reaction (PCR) Fluorescence In-Situ Hybridization (FISH) Immunohistochemistry (IHC) Others

Genomic Cancer Panel & Profiling Market, By End-User:

Hospitals Clinical and Diagnostic Laboratories Others

Genomic Cancer Panel & Profiling Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Genomic Cancer Panel & Profiling Market.

Available Customizations:

Global Genomic Cancer Panel & Profiling Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Genomic Cancer Panel & Profiling Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Tissue Testing (Solid Tissue Testing, Liquid Tissue Testing)
  • 5.2.2. By Cancer Panel Type (Single-Gene Panel, Multi-Gene Panel)
  • 5.2.3. By Cancer Type (Lung Cancer, Breast Cancer, Colon Cancer, Prostate Cancer, Others)
  • 5.2.4. By Application (Clinical, Research)
  • 5.2.5. By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In-Situ Hybridization (FISH), Immunohistochemistry (IHC), Others)
  • 5.2.6. By End-User (Hospitals, Clinical and Diagnostic Laboratories, Others)
  • 5.2.7. By Region
  • 5.2.8. By Company (2023)
• 5.3. Market Map
  • 5.3.1. By Tissue Testing
  • 5.3.2. By Cancer Panel Type
  • 5.3.3. By Cancer Type
  • 5.3.4. By Application
  • 5.3.5. By Technology
  • 5.3.6. By End-User
  • 5.3.7. By Region

6. Asia Pacific Genomic Cancer Panel & Profiling Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Tissue Testing
  • 6.2.2. By Cancer Panel Type
  • 6.2.3. By Cancer Type
  • 6.2.4. By Application
  • 6.2.5. By Technology
  • 6.2.6. By End-User
  • 6.2.7. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Genomic Cancer Panel & Profiling Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Tissue Testing
      • 6.3.1.2.2. By Cancer Panel Type
      • 6.3.1.2.3. By Cancer Type
      • 6.3.1.2.4. By Application
      • 6.3.1.2.5. By Technology
      • 6.3.1.2.6. By End-User
  • 6.3.2. India Genomic Cancer Panel & Profiling Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Tissue Testing
      • 6.3.2.2.2. By Cancer Panel Type
      • 6.3.2.2.3. By Cancer Type
      • 6.3.2.2.4. By Application
      • 6.3.2.2.5. By Technology
      • 6.3.2.2.6. By End-User
  • 6.3.3. Australia Genomic Cancer Panel & Profiling Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Tissue Testing
      • 6.3.3.2.2. By Cancer Panel Type
      • 6.3.3.2.3. By Cancer Type
      • 6.3.3.2.4. By Application
      • 6.3.3.2.5. By Technology
      • 6.3.3.2.6. By End-User
  • 6.3.4. Japan Genomic Cancer Panel & Profiling Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Tissue Testing
      • 6.3.4.2.2. By Cancer Panel Type
      • 6.3.4.2.3. By Cancer Type
      • 6.3.4.2.4. By Application
      • 6.3.4.2.5. By Technology
      • 6.3.4.2.6. By End-User
  • 6.3.5. South Korea Genomic Cancer Panel & Profiling Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Tissue Testing
      • 6.3.5.2.2. By Cancer Panel Type
      • 6.3.5.2.3. By Cancer Type
      • 6.3.5.2.4. By Application
      • 6.3.5.2.5. By Technology
      • 6.3.5.2.6. By End-User

7. Europe Genomic Cancer Panel & Profiling Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Tissue Testing
  • 7.2.2. By Cancer Panel Type
  • 7.2.3. By Cancer Type
  • 7.2.4. By Application
  • 7.2.5. By Technology
  • 7.2.6. By End-User
  • 7.2.7. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Genomic Cancer Panel & Profiling Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Tissue Testing
      • 7.3.1.2.2. By Cancer Panel Type
      • 7.3.1.2.3. By Cancer Type
      • 7.3.1.2.4. By Application
      • 7.3.1.2.5. By Technology
      • 7.3.1.2.6. By End-User
  • 7.3.2. Germany Genomic Cancer Panel & Profiling Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Tissue Testing
      • 7.3.2.2.2. By Cancer Panel Type
      • 7.3.2.2.3. By Cancer Type
      • 7.3.2.2.4. By Application
      • 7.3.2.2.5. By Technology
      • 7.3.2.2.6. By End-User
  • 7.3.3. Spain Genomic Cancer Panel & Profiling Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Tissue Testing
      • 7.3.3.2.2. By Cancer Panel Type
      • 7.3.3.2.3. By Cancer Type
      • 7.3.3.2.4. By Application
      • 7.3.3.2.5. By Technology
      • 7.3.3.2.6. By End-User
  • 7.3.4. Italy Genomic Cancer Panel & Profiling Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Tissue Testing
      • 7.3.4.2.2. By Cancer Panel Type
      • 7.3.4.2.3. By Cancer Type
      • 7.3.4.2.4. By Application
      • 7.3.4.2.5. By Technology
      • 7.3.4.2.6. By End-User
  • 7.3.5. United Kingdom Genomic Cancer Panel & Profiling Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Tissue Testing
      • 7.3.5.2.2. By Cancer Panel Type
      • 7.3.5.2.3. By Cancer Type
      • 7.3.5.2.4. By Application
      • 7.3.5.2.5. By Technology
      • 7.3.5.2.6. By End-User

8. North America Genomic Cancer Panel & Profiling Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Tissue Testing
  • 8.2.2. By Cancer Panel Type
  • 8.2.3. By Cancer Type
  • 8.2.4. By Application
  • 8.2.5. By Technology
  • 8.2.6. By End-User
  • 8.2.6. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Genomic Cancer Panel & Profiling Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Tissue Testing
      • 8.3.1.2.2. By Cancer Panel Type
      • 8.3.1.2.3. By Cancer Type
      • 8.3.1.2.4. By Application
      • 8.3.1.2.5. By Technology
      • 8.3.1.2.6. By End-User
  • 8.3.2. Mexico Genomic Cancer Panel & Profiling Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Tissue Testing
      • 8.3.2.2.2. By Cancer Panel Type
      • 8.3.2.2.3. By Cancer Type
      • 8.3.2.2.4. By Application
      • 8.3.2.2.5. By Technology
      • 8.3.2.2.6. By End-User
  • 8.3.3. Canada Genomic Cancer Panel & Profiling Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Tissue Testing
      • 8.3.3.2.2. By Cancer Panel Type
      • 8.3.3.2.3. By Cancer Type
      • 8.3.3.2.4. By Application
      • 8.3.3.2.5. By Technology
      • 8.3.3.2.6. By End-User

9. South America Genomic Cancer Panel & Profiling Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Tissue Testing
  • 9.2.2. By Cancer Panel Type
  • 9.2.3. By Cancer Type
  • 9.2.4. By Application
  • 9.2.5. By Technology
  • 9.2.6. By End-User
  • 9.2.7. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Genomic Cancer Panel & Profiling Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Tissue Testing
      • 9.3.1.2.2. By Cancer Panel Type
      • 9.3.1.2.3. By Cancer Type
      • 9.3.1.2.4. By Application
      • 9.3.1.2.5. By Technology
      • 9.3.1.2.6. By End-User
  • 9.3.2. Argentina Genomic Cancer Panel & Profiling Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Tissue Testing
      • 9.3.2.2.2. By Cancer Panel Type
      • 9.3.2.2.3. By Cancer Type
      • 9.3.2.2.4. By Application
      • 9.3.2.2.5. By Technology
      • 9.3.2.2.6. By End-User
  • 9.3.3. Colombia Genomic Cancer Panel & Profiling Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Tissue Testing
      • 9.3.3.2.2. By Cancer Panel Type
      • 9.3.3.2.3. By Cancer Type
      • 9.3.3.2.4. By Application
      • 9.3.3.2.5. By Technology
      • 9.3.3.2.6. By End-User

10. Middle East and Africa Genomic Cancer Panel & Profiling Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Tissue Testing
  • 10.2.2. By Cancer Panel Type
  • 10.2.3. By Cancer Type
  • 10.2.4. By Application
  • 10.2.5. By Technology
  • 10.2.6. By End-User
  • 10.2.7. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Genomic Cancer Panel & Profiling Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Tissue Testing
      • 10.3.1.2.2. By Cancer Panel Type
      • 10.3.1.2.3. By Cancer Type
      • 10.3.1.2.4. By Application
      • 10.3.1.2.5. By Technology
      • 10.3.1.2.6. By End-User
  • 10.3.2. Saudi Arabia Genomic Cancer Panel & Profiling Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Tissue Testing
      • 10.3.2.2.2. By Cancer Panel Type
      • 10.3.2.2.3. By Cancer Type
      • 10.3.2.2.4. By Application
      • 10.3.2.2.5. By Technology
      • 10.3.2.2.6. By End-User
  • 10.3.3. UAE Genomic Cancer Panel & Profiling Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Tissue Testing
      • 10.3.3.2.2. By Cancer Panel Type
      • 10.3.3.2.3. By Cancer Type
      • 10.3.3.2.4. By Application
      • 10.3.3.2.5. By Technology
      • 10.3.3.2.6. By End-User
  • 10.3.4. Egypt Genomic Cancer Panel & Profiling Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Tissue Testing
      • 10.3.4.2.2. By Cancer Panel Type
      • 10.3.4.2.3. By Cancer Type
      • 10.3.4.2.4. By Application
      • 10.3.4.2.5. By Technology
      • 10.3.4.2.6. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Genomic Cancer Panel & Profiling Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Agilent Technologies, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (In case of listed)
  • 15.1.5. Recent Developments
  • 15.1.6. SWOT Analysis
• 15.2. ARUP Laboratories Inc
• 15.3. Burning Rock Biotech Limited
• 15.4. U.S. Caris MPI, Inc.
• 15.5. Danaher Corporation
• 15.6. Exact Sciences Corporation
• 15.7. F. Hoffmann-La Roche Ltd
• 15.8. Fulgent Genetics Inc.
• 15.9. Illumina, Inc.
• 15.10. Thermo Fisher Scientific Inc.

16. Strategic Recommendations

17. About Us & Disclaimer